Log In
Print
BCIQ
Print
Print this Print this
 

MGN1601

  Manage Alerts
Collapse Summary General Information
Company Mologen AG
DescriptionTumor vaccine consisting of allogeneic tumor cells genetically modified to express IL-7, GM-CSF, CD80 (B7-1) and CD40 ligand (CD40LG; CD40L; CD154) in combination with a DNA immunomodulator
Molecular Target Interleukin-7 (IL-7) ; Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)
Mechanism of ActionGene therapy; Vaccine
Therapeutic ModalityGene therapy: Non-viral vector
Latest Stage of DevelopmentPhase I/II
Standard IndicationRenal cancer
Indication DetailsTreat advanced renal cell carcinoma (RCC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today